Kynexis
About:
Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).
Website: https://www.kynexistx.com/
Twitter/X: KynexisTx
Top Investors: Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures
Description:
Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).
Total Funding Amount:
57M EUR
Headquarters Location:
Naarden, Noord-Holland, The Netherlands
Founded Date:
2023-01-01
Founders:
Number of Employees:
11-50
Last Funding Date:
2023-11-07
IPO Status:
Private
Industries:
© 2025 bioDAO.ai